arrow_back Back Filing freshness 20-F FY 2025 SEC EDGAR

Burning Rock Biotech Ltd

BNR
$13.26 ▲ +0.37 (+2.87%) at close
Healthcare ·Services-Medical Laboratories ·USServices-Medical Laboratories
7 Visible periods
21 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

Burning Rock Biotech Ltd faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —
Dividend Yield —
Revenue Growth 9.2% ↗
Op. Margin -10.2% ↗
ROIC -8.1% ↗
FCF / Share —
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

7-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$77.16M
↑ +9.2% —
Net Income Profit after all expenses
$-7.92M
↑ +83.3% —
Operating Margin Operating profit as % of sales
-10.2%
↑ +85.3% 15th
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
15
Returns ↑
34
Financial Health ↓
3
Cash Quality ↓
44

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 7 years · 7 quarters